Clinical Trial Search

Primary: PTH (Parathyroid Hormone) Adherence — 0.23; 0.28 probability of having a PTH measured — p=0.04

Primary: Number of Participants With CKD Diagnosis — 417; 389 Participants — p=.21

Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%

Primary: Change in Urinary Albumin Excretion From Baseline to 4 Months — -28.6; -5.6 mg/g — p=0.17

Primary: Mortality — 0; 0 percentage of mortality

Primary: Number of Participants With Treatment-related Adverse Events — 0 Participants

Primary: Change From Baseline in eGFR at 3 Months (Patient-specific) — -1.71; -4.12 ml/min/1.73m^2

Primary: Effect of Vitamin D Supplementation on Albuminuria in CKD Patients as Assessed by Urine Albumin/Creatinine Measures. — 1126.68; 1061.39 mg/gram creatinine

Primary: Phosphocreatine (PCR) Recovery Time After Knee Extension Assessed by 31 Phosphorus Magnetic Resonance Spectroscopy (31P-MRS) — 60.59; 62.66 seconds

Primary: Change From Baseline in eGFR at 6 Months (Patient-specific) — -2.35; -4.24 mL/min/1.73m^2

Primary: Patient Activation Measure (PAM) -13 Item Questionnaire — 9.1; -1.4 points — p=0.01

Primary: Monocyte Protein Expression — 34110; 38540; 1359; 1360 relative fluorescence units

Primary: Qualitative Survey Assessmentof Perceived Usefulness of the Med-alert Device. — 1 Likert scale

Primary: Peak Oxygen Consumption — 3.07 ml/min/kg

Primary: Percent Change From Baseline to Day 169 (Week 24) in UACR - Per Protocol Population — -14.82; -17.25; -31.45; -29.70 Percentage change from baseline — p=0.8338

Primary: Change in Quantitative Computed Tomography (QCT) Bone Mineral Density of the Hip — -10.71; 5.72; -3.52; .2 g/cm^3 — p=.443

Primary: Change in Urine Albumin Excretion — -21; -5 percent difference

Primary: Systolic Blood Pressure (SBP) — 135.1; 134.4 mmHg — p=0.57

Primary: Fibroblast Growth Factor 23 (FGF-23) — 162.695; 297; 188.975; 143.7675 RU/ml

Primary: the Occurrence of Cardiovascular Event and Peritonitis Events — 0; 0; 0; 0 participants — p=>0.05

Primary: The Blood Levels of Calcium at the 24th Month of Following up. — 2.31; 2.33 mmol/L — p=0.117

Primary: Mean Feasibility of Intervention Measure — 16.4; 16.1; 19.0 score on a scale

Primary: The Patient Activation Measure (PAM) — 60.8; 61.5; 1.73; 3.44 score on a scale

Primary: Compare the Difference Between the Calcitriol and Cholecalciferol Groups in Conduit Artery Endothelium-dependent Dilation (EDD) in Response to Treatment. — -0.5; 0.3…

Primary: Change is Leptin to Adiponectin Ratio (LAR) — 2.2; 1.3; 1.3; 1.4 ng/micrograms

Primary: Renal Failure Event Defined as Greater Than or Equal to 40% Decline in Estimated Glomerular Filtration Rate (eGFR) or Occurrence of End Stage Renal Disease (ESRD) — 9.7…

Primary: Number of Participants Achieving a Composite Endpoint of Initiation of Maintenance Dialysis or All-cause Mortality — 35; 46 Participants — p=.1602

Primary: Difference in Mean CKD Register Patient eGFRs Between Groups After 3.5 Years of Study — -2.00; -2.29 mean average eGFR change/mL/min/1.73 m^2

Primary: Percentage of Participants Achieving an Intact Parathyroid Hormone (iPTH) Level Within the Target Range — 28.4; 43.3; 35.8; 38.8 percentage of participants

Primary: Achievement of a ≥ 30% Reduction in Mean PTH From Baseline to During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26) — 96; 58; 57; 93 participants — p=<0.0001